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Abstract Cushing syndrome (CS) is characterized by
increased morbidity and mortality compared to the general
population. However, there are patients who have more
clinical aggressive forms than others. Aim of the study is to
evaluate whether the degree of hypercortisolism, defined by
the number of times urinary free cortisol (UFC) levels
exceed the upper limit of the normal range (ULN), is related
to the worsening of phenotypic features, as well as metabolic
and cardiovascular parameters, in a cohort of CS patients. A
cross-sectional study was conducted on 192 patients with
active CS, consecutively presenting at the outpatients’ clinic
of the University Hospitals of Ancona, Naples, and Palermo.
Patients were grouped into mild (UFC not exceeding twice
the ULN), moderate (2–5 times the ULN), and severe (more
than 5 times the ULN) hypercortisolism. Thirty-seven
patients (19.3 %) had mild, 115 (59.8 %) moderate, and 40
(20.9 %) severe hypercortisolism. A significant trend of
increase among the three groups was demonstrated for 8-,
16-, and 24-h serum cortisol levels (p\ 0.001) and serum
cortisol after low dose of dexamethasone suppression test
(p = 0.001). No significant trend of increase was found
regarding phenotype and comorbidities. The degree of
hypercortisolism by itself does not appear to be a sufficient
parameter to express the severity of CS. Therefore, esti-
mating the severity of CS according to biochemical param-
eters remains a challenge, while the clinical phenotype and
the associated comorbidities might be more useful to
assessing the severity of the CS.
Keywords Cushing syndrome severity  Urinary free
cortisol  Cushing syndrome comorbidities  Degree of
hypercortisolism
Introduction
Cushing syndrome (CS) is caused by prolonged exposure
to inappropriately high levels of cortisol. It is the conse-
quence of a pituitary or extrapituitary ACTH-secreting
tumor (respectively 70–75 and 5–10 % of cases), which in
turn stimulate cortisol overproduction from adrenal glands,
while in few patients it may depend on an adrenal tumor or
hyperplasia (10–20 % of cases) [1–4].
CS is associated with increased mortality rate compared
to general population mainly due to cardiovascular disease,
direct consequence of the several comorbidities associated
with CS, but also to infectious diseases, and consequent
sepsis as result of the immunosuppression induced by
hypercortisolism [5–12]. However, the mortality rate seems
to be strongly dependent by the disease status. Patients with
persistent or recurrent disease show a dramatically
increased mortality compared to the general population,
while patients who obtain the surgical remission seem to
have a mortality rate similar to that of general population,
even though some discrepancies have been reported [13].
Indeed, different retrospective studies reported a main-
tained increased mortality compared to general population,
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even in patients who achieved the remission [14–16], due
to the persistence of several comorbidities and strongly
dependent on the duration of exposure to glucocorticoid
excess.
Therefore, an immediate therapeutic action is required
in patients with CS in order to improve life expectancy
[17].
Obviously, patients do not have the same degree of the
disease. A subgroup of patients shows an early onset, with
a different severity of complications at diagnosis, sug-
gesting the interaction of many factors in inducing the
aggressiveness of the disease. However, all these patho-
genetic factors are not completely known. Maybe, the
degree and duration of hypercortisolism have a crucial role,
even though other factors might have an influence in
determining CS complications [18, 19].
To date, in agreement with the Endocrine Society
guidelines, the recommended parameters to diagnose CS
hypercortisolism are measurement of 24-h urinary free
cortisol (UFC), late-night salivary cortisol (LNSC), and
serum cortisol after low dose (1 mg) of dexamethasone
suppression test (LDDST) [20]. However, in some clinical
trials, patients with CD have been grouped into patients
with mild, moderate, severe, and very severe hypercorti-
solism according to UFC levels, evaluated in terms of the
number of times they exceed the upper limit of the normal
range (ULN) [21, 22]. This arbitrary grouping might rep-
resent a way to differentiate patients according to the
severity of CD, even though no studies have been con-
ducted to demonstrate its effectiveness.
Therefore, the aim of this study was to evaluate whether
the degree of hypercortisolism, based on the ULN of UFC
levels, is related to severity of clinical, metabolic, and
cardiovascular picture, in a large cohort of patients with
active CS.
Materials and methods
Patients and study design
The current study is based on a retrospective analysis of
data collected from 192 patients (males 19.8 % and
females 80.2 %) with active CS (71.8 % with pituitary and
28.2 % with adrenal dependent disease), recruited at the
Endocrinology Units of the University Hospitals of
Ancona, Naples, and Palermo between 2000 and 2013.
The diagnosis of CS was based, in accordance with the
international criteria, on high daily UFC levels (at least
three samples), absent cortisol suppression after LDDST
(\1.8 lg/dl), and lack of cortisol rhythm (midnight cortisol
levels\7.5 lg/dl) [20]. In addition, the diagnosis of CD
was based on high or inappropriately normal serum ACTH
levels, magnetic resonance imaging confirmation of a
pituitary tumor, or an ACTH central-peripheral gradient[2
at baseline and/or [3 after corticotrophin-releasing hor-
mone (CRH) or desmopressin (DDAVP) stimulation at
inferior petrosal sinus sampling [20]. Exclusion criteria
were subclinical CS, adrenal, or pituitary cancer. No
women taking oral contraceptives were included.
This study was approved by the Institutional Review
Boards at each center. At the time of hospitalization, all
patients provided written informed consent for the scien-
tific use of their data. The identity of the participation
remained anonymous during database analysis.
All patients at the diagnosis had undergone a complete
hormonal evaluation of the pituitary–adrenal axis. Three
24-h urine samples had been collected to calculate the
mean UFC (mUFC) for each patient. Then, for all patients
with high mUFC, the serum cortisol after low dose of
dexamethasone (1 mg) and the 8-, 16-, and 24-h serum
cortisol and ACTH levels had been performed.
Patients were subdivided into three groups according to
mUFC. Mild hypercortisolism was defined by mUFC levels
B33th percentile (approximately equivalent to UFC level
not exceeding 2 times the ULN). Moderate hypercorti-
solism was defined by a level of mUFC more than 34th to
66th percentile (approximately equivalent to UFC level
more than 2–5 times the ULN). Severe hypercortisolism
was defined by a mUFC C 67th percentile (approximately
equivalent to UFC level more than five times the ULN).
Clinical parameters such as BMI, systolic and diastolic
blood pressure, measured according to international criteria
[23], waist circumference (WC), measured at the midpoint
between the lower rib and the iliac crest, and waist/hip ratio
(WHR) were retrospectively obtained. The mean duration
of the disease was established by patient interview,
patients’ clinical pictures, and beginning of the weight
increase.
Some phenotypic parameters such as muscle hypotro-
phy, moon face, facial plethora, buffalo hump, and purple
striae evaluated by clinical examination, were drawn out.
As comorbidities, the study included the cardiovascular
complications such as coronary heart disease, vascular
disease (central and peripheral), and thrombotic events,
infections, hypokalemia, the metabolic complications such
as metabolic syndrome and impairment of glucose meta-
bolism, the depression and the bone complications such as
osteoporosis/osteopenia and vertebral and non-fractures.
All these data had been obtained by patient interviews,
laboratory, and instrumental data.
After an overnight fast, lipids [total cholesterol (C),
HDL-C, LDL-C, and triglycerides (TG)], HbA1c, gly-
caemia, insulin, coagulation parameters, calcium, phos-
phorus, parathyroid hormone (PTH), and hepatic and renal
functions had been evaluated. The insulin sensitivity was
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indirectly estimated using basal insulin and glucose values
to calculate the homeostatic model of insulin resistance
(HOMA2-IR) [glycaemia (mmol/l) 9 insulinemia (mU/
ml)/22.5] [24]. In a subgroup of 70 patients who had
undergone oral glucose tolerance test (OGTT) the Matsuda
index of insulin sensitivity (ISI Matsuda) [10000/glucose
(mg/dl) 9 insulin (mU/ml) 9 glucose mean x insulin
mean] [25], the oral disposition index (DIo) [(DInsulin0–30/
DGlucose0–30) 9 (1/fasting insulin)] [26], and the area
under the curve for insulin (AUC2-h insulin) and glucose
(AUC2-h glucose) were calculated.
The HOMA-b was calculated as [(360 9 Insulin)/
(Glucose—63) % (Glucose in mg/dl)] [23]. The visceral
adiposity index (VAI) was calculated according to gender,
where TG levels were expressed in mmol/l and HDL levels
were expressed in mmol/l:
– Males VAI ¼ WC=39:68þ 1:88 BMIð Þ½  
TG=1:03ð Þ  1:31=HDLð Þ
– Females VAI ¼ WC=36:58þ 1:89 BMIð Þ½  
TG=0:81ð Þ  1:52=HDLð Þ [27].
The metabolic syndrome (MS) was diagnosed according
to the NCEP ATP III criteria, whereas DM and prediabetes
were diagnosed according to the ADA criteria [28].
All patients included in the study who had surgery, had a
subsequent histological confirmation of the CS.
Hormone and biochemical assays
Serum glutamic oxaloacetic transaminase (GOT) and glu-
tamic pyruvic transaminase (GPT), creatinine, bone
markers such as calcium, phosphorus, PTH, clotting fac-
tors, insulin, glycaemia, HbA1c, and lipids were measured
by standard methods for each center. LDL-C levels were
calculated using the Friedewald formula [total choles-
terol - (HDL ? (TG/5)]. UFC levels had been detected by
electrochemiluminescence immunoassay (ECLIA) (Elec-
sys cortisol reagent kit with prior dichloromethane
extraction to reduce the amount of cortisol metabolites and
conjugates) in patients from Ancona and Palermo, and by
Immulite, solid-phase chemiluminescent enzyme
immunoassay (DPC, Los Angeles, CA, USA) in patients
from Naples. A correction of UFC for creatinine concen-
tration had been performed dividing UFC by urinary cre-
atinine excretion. The normal range for UFC was 10–110,
35–135, and 36–137 lg/24 h, respectively for Ancona,
Naples, and Palermo.
Serum cortisol was evaluated using the electrochemi-
luminescent (ECLIA) automated method Access (Beckman
Coulter, Brea, CA, USA) for Palermo and Ancona, by
Immulite, solid-phase chemiluminescent enzyme
immunoassay (DPC, Los Angeles, CA, USA) for Naples.
The intra- and inter-assay coefficients of variation for
serum and urinary cortisol were 1.2 and 1.4 % for Ancona
and Palermo and 6.04 and 7.78 % for Naples. The con-
version factors for the International System (SI) were as
follows: glucose mg/dl versus mmol/l: 0.0555; insulin
mUI/ml versus pmol/l: 6.945; total cholesterol and HDL-C
mg/dl versus mmol/l: 0.0259; triglycerides mg/dl versus
mmol/l: 0.0113; cortisol ng/ml versus nmol/l: 2.76; UFC
microg/24 h versus nmol/24 h: 2.76.
Statistical analysis
The Statistical Packages for Social Science SPSS version
17 (SPSS, Inc.) was used for data analysis. The normality
of quantitative variables was tested with the Shapiro–Wilk
test. Baseline characteristics were presented as mean ± SD
for continuous variables, while rates and proportions were
calculated for categorical data. The ANOVA trend analysis
for quantitative variables and v2 for trend for categorical
variables were carried out for the three groups: mild,
moderate, and severe. Simple univariate correlations
among continuous variables with non-normal distribution
were determined by Spearman test. A p value\0.05 was
considered to be statistically significant.
Results
Patients were classified as having a mild (19.2 %), mod-
erate (59.8 %), and severe hypercortisolism (20.8 %).
Clinical and phenotypic characteristics and the duration
of disease of all patients are shown in Table 1. No signif-
icant trend was found among the three groups of patients
for the above-mentioned parameters.
Comorbidities of patients are shown in Table 2. No
significant trend was observed for cardiovascular and
thrombotic complications, infections, hypokalemia, psy-
chiatric, bone, and metabolic comorbidities.
The biochemical parameters of all patients are shown in
Table 3. No significant trend was observed for lipids,
glucose, insulin sensitivity and secretion indexes, and
clotting parameters among the three groups of patients.
A significant trend of increase was observed in 8-, 16-,
and 24-h serum cortisol and similarly in serum cortisol
after LDDST (Fig. 1). A strong correlation between the
ULN of UFC and 8 h cortisol (Rho 0.339, p\ 0.001)
(Fig. 1a), ULN of UFC and 16 h cortisol (Rho 0.336
p\ 0.001) (Fig. 1b), ULN of UFC and 24 h cortisol (Rho
0.400, p\ 0.001) (Fig. 1c), and ULN of UFC and serum
cortisol after LDDST (Rho 0.308, p\ 0.0001) (Fig. 1d)
was found.
Comparing patients with adrenal and pituitary disease
not significant differences were found for the ULN of UFC
(p 0.173), 8 h cortisol (p 0.936), 16 h cortisol (0.830), 24 h
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Table 1 Clinical and
phenotypic parameters of all
192 Cushing patients grouped
according to the degree of
hypercortisolism, in mild,
moderate, and severe
Mild (N = 37) Moderate (N = 115) Severe (N = 40) p
Mean ± SD Mean ± SD Mean ± SD
Clinical parameters
Age (year) 45.59 ± 17.64 43.71 ± 16.25 38.83 ± 17.40 0.075
BMI (Kg/m2) 31.29 ± 8.52 30.87 ± 5.0 29.62 ± 5.23 0.316
WC (cm) 100.76 ± 19.72 105.80 ± 15.42 95.55 ± 16.01 0.140
WHR 0.98 ± 0.08 1.02 ± 0.09 0.98 ± 0.06 0.863
Duration of disease
(months)
33.38 ± 24.6 28.8 ± 28.37 33.65 ± 26.98 0.513
Subjects (%) Subjects (%) Subjects (%)
Gender
Female 30 (81.1 %) 93 (80.9 %) 31 (77.5 %) 0.680
Male 7 (18.9 %) 22 (19.1 %) 9 (22.5 %) 0.700
Pituitary dependent 24 (64.9 %) 81 (70.4 %) 33 (82.5 %) 0.082
Adrenal dependent 13 (35.1 %) 34 (29.6 %) 7 (17.5 %)
Phenotypic parameters
Moon face 24 (64.9 %) 54 (47.0 %) 22 (55 %) 0.416
Facial Plethora 18 (48.6 %) 63 (54.8 %) 20 (50 %) 0.978
Buffalo hump 16 (43.2 %) 43 (37.4 %) 11 (27.5 %) 0.148
Purple striae 14 (37.8 %) 35 (30.8 %) 19 (47.5 %) 0.348
Table 2 Comorbidities of all
192 Cushing patients grouped
according to the degree of
hypercortisolism, in mild,
moderate, and severe
Mild (N = 37) Moderate (N = 115) Severe (N = 40) P
Subjects (%) Subjects (%) Subjects (%)
Cardiovascular and thrombotic complications
Coronary heart disease 8 (21.6 %) 26 (22.6 %) 7 (17.5 %) 0.648
Thromboembolic events 6 (16.5 %) 7 (6.1 %) 3 (7.5 %) 0.180
Peripheral vascular disease 6 (16.2 %) 7 (6.1 %) 2 (5 %) 0.172
Cerebral vascular disease 3 (8.1 %) 9 (7.8 %) 4 (10 %) 0.757
Psychiatric complications
Depression 7 (18.9 %) 23 (20.0 %) 12 (30 %) 0.231
Infections 6 (16.2 %) 9 (7.8 %) 2 (5 %) 0.087
Hypokalemia 7 (18.9 %) 16 (13.9 %) 7 (17.5 %) 0.586
Bone complications
Osteoporosis/osteopenia 11 (29.7 %) 27 (23.5 %) 16 (40 %) 0.292
Non-vertebral fractures 6 (16.2 %) 12 (10.4 %) 2 (5 %) 0.107
Vertebral collapse 2 (5.4 %) 16 (13.9 %) 3 (7.5 %) 0.806
Metabolic complications
Metabolic syndrome*** 22 (59.5 %) 69 (60 %) 19 (47.5 %) 0.276
High Blood pressure*** 24 (64.9 %) 88 (76.5 %) 25 (62.5 %) 0.773
High Triglycerides*** 12 (32.4 %) 42 (36.5 %) 12 (30 %) 0.804
Low HDL Cholesterol*** 17 (45.9 %) 58 (50.4 %) 12 (30 %) 0.145
Increased WC*** 27 (73 %) 95 (82.6 %) 27 (67.5 %) 0.524
Hypercholesterolemia 15 (40.5 %) 50 (47 %) 17 (42.5 %) 0.873
Impaired fasting glucose (IFG) 1 (2.7 %) 7 (6.1 %) 0 0.521
Impaired glucose tolerance (IGT) 2 (5.4 %) 18 (15.7 %) 3 (7.5 %) 0.822
IFG ? IGT 0 1 (0.9 %) 1 (2.5 %) 0.276
Diabetes mellitus 12 (32.4 %) 35 (30.4 %) 14 (35 %) 0.797
*** According to Adult Treatment Panel (ATP) III criteria
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cortisol (0.764), and serum cortisol after LDDST (0.139)
(data not shown).
Discussion
Currently, many studies show a relation between hyper-
cortisolism and some conditions such as cognitive function
impairment, depression, cardiovascular disease, infections,
and metabolic syndrome [29–32]. However, little is known
about a possible association between the degree of hyper-
cortisolism and the aggressiveness of the syndrome.
This study shows that the degree of hypercortisolism
evaluated by UFC levels, based on the number of times they
exceed the ULN, is not correlated with the prevalence and
severity of cardiovascular and thrombotic complications,
infections, bone and psychiatric comorbidities, and impair-
ment of phenotypical and metabolic parameters including
insulin sensitivity and secretion indexes and VAI. This is an
interesting finding because it might be expected that high
UFC levelswould correlate with the prevalence and intensity
of phenotypic features and complications.
The results of the current study confirm and expand
those of a previous series, showing that UFC levels alone
Table 3 Biochemical parameters of all 192 Cushing patients grouped according to the degree of hypercortisolism, in mild, moderate, and severe
Mild (N = 37) Moderate (N = 115) Severe (N = 40)
Mean ± SD Mean ± SD Mean ± SD p
Metabolic and general parameters
Total Cholesterol (mmol/l) 5.30 ± 0.86 5.15 ± 0.97 5.32 ± 1.05 0.911
HDL Cholesterol (mmol/l) 1.32 ± 0.39 1.34 ± 0.37 1.41 ± 0.37 0.343
LDL cholesterol (mmol/l) 3.12 ± 0.85 3.04 ± 0.83 3.04 ± 1.01 0.681
Triglycerides (mmol/l) 1.68 ± 0.97 1.61 ± 0.82 1.65 ± 1.16 0.901
Fasting glucose (mmol/l) 5.95 ± 2.65 6.07 ± 2.18 5.25 ± 1.39 0.143
Fasting insulin (UI/ml) 11.34 ± 0.67 13.66 ± 6.85 11.87 ± 5.41 0.745
GOT (mg/dl) 25.4 ± 17.1 19.8 ± 7.05 18.10 ± 4.75 0.124
GPT (mg/dl) 34.63 ± 21.7 32.3 ± 18.17 35.4 ± 19.75 0.936
Calcium (mg/dl) 9.6 ± 0.54 9.45 ± 0.51 9.35 ± 0.46 0.174
Phosphorus (mg/dl) 3.81 ± 0.4 3.63 ± 0.7 3.45 ± 0.6 0.115
PTH (pg/ml) 44.1 ± 24.13 48.01 ± 30.76 45.62 ± 26.27 0.832
Creatinin (mg/dl) 0.95 ± 0.27 0.87 ± 0.28 0.89 ± 0.23 0.613
HbA1c (%) 6.5 ± 1.3 6.5 ± 1.32 6.31 ± 1.17 0.651
HbA1c (mmol/mol) 48 ± 0.9 48 ± 0.9 45 ± 0.1 0.651
VAI 2.69 ± 2.02 2.63 ± 1.72 2.40 ± 2.13 0.492
AUC 2h glucose* (mmol/l 120 min) 1042.63 ± 321.33 993.51 ± 378.48 1064.17 ± 368.7 0.800
Insulin sensitivity indexes
Homa 2-IR 1.66 ± 0.6 2.03 ± 1.03 1.68 ± 0.79 0.995
ISI Matsuda* 4.83 ± 3.35 4.05 ± 3.53 3.98 ± 1.66 0.522
Insulin secretion indexes
Homa b 129.71 ± 68.31 136.45 ± 80.25 141.65 ± 55.85 0.479
AUC 2h insulin* (nmol/l 120 min) 7739.12 ± 4830.2 10842.8 ± 6951.5 7959.2 ± 3660.6 0.845
Oral Disposition Index (DIo)* 3.10 ± 5.74 1.58 ± 1.55 1.68 ± 2.15 0.216
Clotting parameters
INR 0.99 ± 0.08 0.94 ± 0.09 1.67 ± 2.86 0.149
aPTT (sec) 28.2 ± 3.81 28.3 ± 4.69 27.1 ± 4.45 0.482
ATIII (%) 107.1 ± 12.18 120.69 ± 39.69 118.0 ± 17.21 0.415
D-Dimer (ng/ml) 206.5 ± 75.6 159.9 ± 147.5 370.7 ± 424.2 0.359
Fibrinogen (mg/dl) 378.2 ± 96.16 347.3 ± 106.1 336.1 ± 106.6 0.232
Hormonal parameters
UFC (nmol/24 h) 4057.9 ± 1297.8 9095.3 ± 2299.9 24.138 ± 5872.5 \0.001
* In a subgroup of 70 patients without known diabetes
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are not suggestive of CS severity [12, 33]. However, in the
study of Petersenn et al. patients had a pituitary disease,
while in our study also patients with adrenal disease were
evaluated.
As known, UFC provides a good assessment of cortisol
secretion over the 24-h period [34]. Measurement of 24-h
UFC excretion has the advantage of being unaffected by
short-term fluctuations in cortisol and by varying plasma
protein binding capacities [35]. 24-h UFC reflects overall
daily cortisol production and, compared to serial blood
sampling, is relatively easy to collect in a large study
population. An important advantage of this method is its
reliability [36], although it is crucially dependent on the
quality and performance of the particular analytical pro-
cedure applied. Indeed, several conditions may result in
falsely elevated values such as alcoholism, high fluid
intake, pregnancy, psychiatric disorders, or in falsely low
levels such as cyclic CS or severe renal function [37, 38].
In this study, UFC levels were analyzed at three different
laboratories, by different techniques, ECLIA and Immulite
analytical procedures, even though the samples belonging
to the same patients were measured in the same laboratory.
In the present study, the concordance between ULN of
UFC and serum cortisol after LDDST and ULN of UFC
and cortisol circadian rhythm (8-, 16-, 24-h cortisol) has
been demonstrated, showing a significant correlation
between these parameters. Unfortunately, concordance
with LNSC has not been performed. However, previous
studies have reported a significant correlation between
UFC and LNSC [39–41], showing even a better perfor-
mance of LNSC compared to UFC in the diagnosis of
Cushing’s syndrome.
In agreement with these results, it has been reported that
some CS complications are not related to the degree of
hypercortisolism, but influenced by a combination of fac-
tors, especially by the duration of glucocorticoid level
exposure. Recently, it has been observed that diabetes in
patients with CS is not strictly dependent on UFC and
serum cortisol levels, but related to other parameters such
as familial history of diabetes, age, and likely duration of
disease [42]. In another study conducted by Zilio et al., no
correlation between UFC and onset of venous throm-
boembolic events were found [43].
However, some authors found a correlation between
hypercortisolism and CS complications. A significant
association of 17 hydroxysteroid progesterone with severe
infections in a cohort of patients with ectopic production of
ACTH was found [44]. Interestingly, the association of
cardiovascular complications with hypercortisolism in CS
was documented in a series of clinical investigations [45–
Fig. 1 Spearman correlation among 8-, 16-, 24-h serum cortisol,
cortisol after LDDST and the ULN of UFC. a Correlation between the
ULN of UFC and 8 h cortisol (Rho 0.339, p\ 0.001). b ULN of UFC
and 16 h cortisol (Rho 0.336 p\ 0.001). c ULN of UFC and 24 h
cortisol (Rho 0.400, p\ 0.001). d ULN of UFC and serum cortisol
after LDDST (Rho 0.308, p\ 0.0001)
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47], showing a strong relationship between these factors. In
addition, an association of hypercortisolism with diabetes
has been suggested in a recent study evaluating the
prevalence of CS in outpatients with poor controlled type 2
diabetes [48].
A further confirmation of the complex and heteroge-
neous variables implicated in CS aggressiveness comes
from the evidence that patients cured from CS maintain
increased cardiovascular risk factors of the active disease,
even in the long term. In a study performed in 25 patients
with CD before and one year after successful treatment, the
persistence of visceral obesity, hypertension, glucose
intolerance, and dyslipidemia was observed, despite clini-
cal and biochemical remission [9]. Similarly, in another
study performed in 15 patients in remission for at least
5 years, the persistence of visceral obesity, hypertension,
impairment of glucose tolerance or diabetes mellitus, and
dyslipidemia were found. Thus, patients with CS in
remission might have a higher incidence of the metabolic
syndrome and vascular disease, due to the persistence of an
insulin resistance state and cardiac damage [49, 50], but
also of psychiatric disorders, compared to the general
population [51–53].
From the data obtained in the current study, it might be
suggested that the degree of hypercortisolism is not the
only parameter that has a role in influencing the severity of
CS, but also the duration of hypercortisolism and the sen-
sitivity to glucocorticoid excess.
Cortisol secretion can be variable, cyclical, and depen-
dent on many factors, making it difficult to assess the
‘‘amount’’ of cortisol production. In this connection, it is
known that there are many factors that influence gluco-
corticoid action such as glucocorticoid receptor (GR)
polymorphisms [18] and the 11 beta-hydroxysteroid-de-
hydrogenase type 1 (11b-HSD1) enzyme [54]. GR poly-
morphisms have been demonstrated to impair
glucocorticoid sensitivity, determining metabolic compli-
cations and bone alterations even in patients with sub-
clinical CS [55]. Some GR polymorphisms such as N363S,
BCL1, and ER22/EK are associated with diabetes, hyper-
tension, and dyslipidemia, while others, such as A3669G,
seem to be protective in CS [18]. Even the 11b-HSD1
enzyme has a prominent role in the regulation of gluco-
corticoid activity, catalyzing the in vivo conversion of
inactive to active glucocorticoids. Transgenic mice over-
expressing 11b-HSD1 in their white adipose tissue are
obese, hypertensive, dyslipidemic, and insulin resistant
[56]. Further, 11b-HSD1 knockout mice are protected from
these metabolic abnormalities [57, 58].
The duration to cortisol exposure might be the prevalent
factor influencing the severity of CS, even though it is a not
well-defined parameter due to a subtle onset of the disease.
In the current study a rough estimate of the duration of
disease was performed. However, no association with UFC
levels was found, even though it might be expected that the
mild hypercortisolism would be associated with a long
duration of disease, while the severe with a short duration
of disease.
In conclusion, the results of the current study show how
difficult is defining CS severity based on UFC. Serum,
salivary, and urinary cortisol values are the current
parameters used to define hypercortisolism ‘‘amount’’,
despite their assays limits. The degree of hypercortisolism
by itself seems not to be a sufficiently exhaustive parameter
to assess the severity of active CS. Predicting the aggres-
siveness of active CS at the diagnosis remains even now a
challenge, due to the difficulty in estimating the duration of
the cortisol exposure and in finding any prognostic hor-
monal markers.
Therefore, currently, the presence of comorbidities seem
to be the most predictive factors for assessing the aggres-
siveness of the active CS.
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